MeiraGTx Holdings (MGTX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.49
- Estimate
- -$0.47
- Surprise
- -3.1%
- Revenue (period 2026-09-30)
- $4.8M
- Score today
- 6.9/10
Revenue source: xbrl.
How the report landed
MeiraGTx Holdings (MGTX) reported a wider loss than forecast — adjusted EPS of -$0.49 against the -$0.47 estimate (a 3.1% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates MGTX Buy (Wait) at 6.9/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -3.1% surprise compares with a +33.4% four-quarter average.
What supports the rating
- High-quality business
- Attractive valuation
What argues against it
- Consecutive earnings misses (2)
- DATA_ISSUE: analyst_target_implausible (raw $27.75 vs price $8.79 — ratio 3.2×). Rejected, falling back to technical TP.
- News modifier -1: STRONG_BUY_NOW → STRONG_BUY_WAIT
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.79
- Entry target
- $8.41
- Price target
- $10.03
- Stop
- $7.82
- Upside to target
- +14.1%
Risk check: trading volume is running 2.1× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-13 — shown for context, not personalized investment advice.
MGTX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $844.2M
- P/E (fwd)
- -5.8
- P/E (ttm)
- 10.1
- 52-week range
- $6.62–$15.35
- Off 52-week high
- 42.7%
- RSI (14)
- 45
- Volume vs avg
- 2.11×
- Score today
- 6.9/10